odanacatib profile

ID Source	ID
PubMed CID	10152654
CHEMBL ID	481611
SCHEMBL ID	1496266
MeSH ID	M0519172

Synonym
HY-10042
CAS:603139-19-1;ODANACATIB
mk-0822;mk 0822;mk0822
bdbm50255753
odanacatib
mk-0822
mk-0822a
603139-19-1
odanacatib (jan/usan)
D08955
CHEMBL481611 ,
mk0822
(2s)-n-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1s)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamide
pentanamide, n-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1s)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2s)-
mk 0822
odanacatib [usan:inn]
l-1037536
unii-n673f6w2vh
n673f6w2vh ,
BCP9001020
BCPP000141
NCGC00346637-01
CS-0277
(2s)-n-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1s)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]pentanamide
S1115
AKOS015900719
odanacatib [mi]
odanacatib [jan]
odanacatib [usan]
odanacatib [who-dd]
odanacatib [mart.]
odanacatib [inn]
c25h27f4n3o3s
gtpl6478
(2s)-n-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1s)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide
smr004676504
MLS006010197
n1-(1-cyanocyclopropyl)-4-fluoro-n2-{(1s)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-l-leucinamide
n1-(1-cyanocyclopropyl)-4-fluoro-n2-{(1s)-2,2,2-trifluoro-1-[4'-(methyl sulfonyl)-1,1'-biphenyl-4-yl]ethyl}-l-leucinamide
n-(1-cyanocyclopropyl)-4-fluoro-n2-{(1s)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-l-leucinamide
mfcd11042419
SCHEMBL1496266
odanacatib (mk-0822)
(s)-n-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-((s)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)biphenyl-4-yl)ethylamino)pentanamide
AC-27468
DTXSID40209075
odanacatib (mk 0822)
J-690332
EX-A552
SW219669-1
DB06670
odanacatib (mk0822)
AS-19562
Q2014070
(s)-n-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-(((s)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)ethyl)amino)pentanamide
CCG-269888
nsc-766811
nsc766811

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	18.7167	AID1259252; AID1259253; AID1259255; AID1259256

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Cathepsin L2	Homo sapiens (human)	IC50	0.7620	AID314224
Procathepsin L	Homo sapiens (human)	IC50	3.9190	AID314221; AID314232
Procathepsin L	Homo sapiens (human)	Ki	1.2589	AID1512166
Cathepsin B	Homo sapiens (human)	IC50	1.3613	AID1918205; AID314220; AID314231
Pro-cathepsin H	Homo sapiens (human)	IC50	0.0100	AID314226
Cathepsin S	Homo sapiens (human)	IC50	0.1970	AID1918204; AID314222; AID314233; AID699425
Cruzipain	Trypanosoma cruzi	Ki	0.1259	AID1512165
Cathepsin K	Homo sapiens (human)	IC50	0.0005	AID1918201; AID314219; AID314228; AID367439; AID458223; AID482895; AID569575; AID699423; AID703434
Cathepsin K	Homo sapiens (human)	Ki	0.0002	AID1402856
Cathepsin K	Oryctolagus cuniculus (rabbit)	IC50	0.0010	AID314229
Dipeptidyl peptidase 1	Homo sapiens (human)	IC50	0.0100	AID314225
Cathepsin Z	Homo sapiens (human)	IC50	0.0100	AID314227
Cathepsin F	Homo sapiens (human)	IC50	0.7950	AID314223

Assay ID	Title	Year	Journal	Article
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1512168	Antitrypanosomal activity against Trypanosoma cruzi Y strain amastigotes infected in human U2OS cells assessed as parasite growth inhibition after 72 hrs post infection by DRAQ5 staining based analysis	2019	Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22 ISSN: 1464-3391	Synthesis and structure-activity relationship of nitrile-based cruzain inhibitors incorporating a trifluoroethylamine-based P2 amide replacement.
AID1918201	Inhibition of Cathepsin K (unknown origin) assessed as inhibition of AFC release using sequence LR labelled with AFC as substrate by fluorescence based analysis	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74ISSN: 1464-3391	Discovery of selective covalent cathepsin K inhibitors containing novel 4-cyanopyrimidine warhead based on quantum chemical calculations and binding mode analysis.
AID314224	Inhibition of cathepsin V	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314221	Inhibition of cathepsin L	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID482899	Selectivity for cathepsin K over cathepsin L	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID367447	Clearance in rat at 2 to 5 mg/kg, iv	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
AID1572834	Inhibition of MMP2 in mouse Primary chondrocytes derived after 2 passages at 1 uM after 24 hrs by Coomassie blue staining-based zymography assay	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 ISSN: 1464-3391	Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.
AID367439	Inhibition of humanized rabbit cathepsin K	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
AID1918202	Inhibition of Cathepsin K (unknown origin) assessed as inhibition of AFC release at 1 uM using sequence LR labelled with AFC as substrate by fluorescence based analysis	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74ISSN: 1464-3391	Discovery of selective covalent cathepsin K inhibitors containing novel 4-cyanopyrimidine warhead based on quantum chemical calculations and binding mode analysis.
AID314219	Inhibition of humanized rabbit cathepsin K	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID569577	Selectivity ratio of IC50 for human cathepsin F to IC50 for human cathepsin K	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID458224	Selectivity ratio of IC50 for human cathepsin B to IC50 for humanized rabbit cathepsin K	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 ISSN: 1464-3405	The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
AID367441	Selectivity ratio of IC50 for human cathepsin S to IC50 for humanized rabbit cathepsin K	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
AID314237	Metabolic stability in human hepatocyte at 20 uM after 2 hrs assessed as recovery of parent compound	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID367443	Half life in rat at 2 to 5 mg/kg, iv	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
AID367440	Selectivity ratio of IC50 for human cathepsin L to IC50 for humanized rabbit cathepsin K	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
AID1918207	Selectivity index, ratio of IC50 for Cathepsin B (unknown origin) to IC50 for Cathepsin K (unknown origin) by fluorescence based analysis	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74ISSN: 1464-3391	Discovery of selective covalent cathepsin K inhibitors containing novel 4-cyanopyrimidine warhead based on quantum chemical calculations and binding mode analysis.
AID569574	Half life in dog at 5 mg/kg, po or 1 mg/kg, iv	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID314223	Inhibition of cathepsin F	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314242	Volume of distribution at steady state in rat at 10 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID1572831	Inhibition of cathepsin K in mouse Primary chondrocytes derived after 2 passages at 1 uM after 24 hrs by Coomassie blue staining-based zymography assay	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 ISSN: 1464-3391	Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.
AID482443	Antiosteoporotic activity in patient with osteoporosis assessed as increase in lumbar spine bone mineral density at 50 mg/kg, po administered weekly for 24 months relative to placebo control	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID699423	Inhibition of human recombinant CatK assessed as suppression of enzyme-mediated Z-Phe-Arg-AMC cleavage incubated for 1 hrs by QFRET assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 ISSN: 1520-4804	(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.
AID314233	Inhibition of cathepsin S in human ramos cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID482895	Inhibition of cathepsin K	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID314220	Inhibition of cathepsin B	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID482423	Selectivity for cathepsin K over cathepsin F	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID569573	Oral bioavailability in dog at 1 mg/kg, iv	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID314239	Oral bioavailability in rat at 10 mg/kg	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID482444	Antiosteoporotic activity in patient with osteoporosis assessed as increase in hip bone mineral density at 50 mg/kg, po administered weekly for 24 months relative to placebo control	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID458485	Decrease in bone resorption assessed as corrected bone resorption measured as ratio of bone resorption IC50 x humanized rabbit cathepsin K IC50 to rabbit cathepsin K IC50 equation	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 ISSN: 1464-3405	The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
AID699425	Inhibition of human recombinant CatS assessed as suppression of enzyme-mediated Z-Val-Val-Arg-AMC cleavage by QFRET assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 ISSN: 1520-4804	(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.
AID703270	Inhibition of osteoclastogenesis in human bone marrow-derived stem cells assessed as reduction of pit formation by measuring TRACP5b activity after 7 days by bone TRAP assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20 ISSN: 1520-4804	Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.
AID314250	Volume of distribution at steady state in rhesus monkey at 5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314225	Inhibition of cathepsin C	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID569576	Selectivity ratio of IC50 for human cathepsin B to IC50 for human cathepsin K	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID703434	Inhibition of cathepsin-k	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20 ISSN: 1520-4804	Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.
AID1572829	Inhibition of cathepsin K in mouse Primary chondrocytes derived after 2 passages at 0.1 to 1 uM using Z-GPR-4MbetaNA as substrate by fluorescence assay relative to control	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 ISSN: 1464-3391	Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.
AID1512166	Inhibition of Cathepsin L (unknown origin) using Z-Phe-Arg-7-amido-4-methylcoumarin as substrate preincubated for 2 mins followed by susbtrate addition by fluorescence based analysis	2019	Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22 ISSN: 1464-3391	Synthesis and structure-activity relationship of nitrile-based cruzain inhibitors incorporating a trifluoroethylamine-based P2 amide replacement.
AID314231	Inhibition of cathepsin B in human HepG2 cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314251	Inhibition of antigen presenting mouse B cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID1572835	Inhibition of MMP9 in mouse Primary chondrocytes derived after 2 passages at 1 uM after 24 hrs by Coomassie blue staining-based zymography assay	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6 ISSN: 1464-3391	Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.
AID314247	Oral bioavailability in rhesus monkey at 5 mg/kg	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID1918203	Inhibition of Cathepsin K (unknown origin) assessed as inhibition of AFC release at 10 uM using sequence LR labelled with AFC as substrate by fluorescence based analysis	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74ISSN: 1464-3391	Discovery of selective covalent cathepsin K inhibitors containing novel 4-cyanopyrimidine warhead based on quantum chemical calculations and binding mode analysis.
AID314235	Metabolic stability in rat hepatocyte at 20 uM after 2 hrs assessed as recovery of parent compound	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID482898	Selectivity for cathepsin K over cathepsin B	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID1918206	Selectivity index, ratio of IC50 for Cathepsin S (unknown origin) to IC50 for Cathepsin K (unknown origin) by fluorescence based analysis	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74ISSN: 1464-3391	Discovery of selective covalent cathepsin K inhibitors containing novel 4-cyanopyrimidine warhead based on quantum chemical calculations and binding mode analysis.
AID1512165	Inhibition of Trypanosoma cruzi cruzain using Z-Phe-Arg-7-amido-4-methylcoumarin as substrate preincubated for 2 mins followed by susbtrate addition by fluorescence based analysis	2019	Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22 ISSN: 1464-3391	Synthesis and structure-activity relationship of nitrile-based cruzain inhibitors incorporating a trifluoroethylamine-based P2 amide replacement.
AID314243	Oral bioavailability in dog at 5 mg/kg	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314232	Inhibition of cathepsin L in human HepG2 cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID482442	Bioavailability in rat	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID482900	Selectivity for cathepsin K over cathepsin S	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID1402856	Inhibition of human cathepsin K	2018	European journal of medicinal chemistry, Jan-20, Volume: 144ISSN: 1768-3254	Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S.
AID569571	Oral bioavailability in rat at 2 mg/kg, iv	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID314241	Half life in rat at 10 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314244	Clearance in dog at 5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314245	Half life in dog at 5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314229	Inhibition of rabbit cathepsin K	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314230	Inhibition of bone resorption in rabbit osteoclast	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID458225	Selectivity ratio of IC50 for human cathepsin F to IC50 for humanized rabbit cathepsin K	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 ISSN: 1464-3405	The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
AID569580	Ratio of product of IC50 for rabbit bone resorption and IC50 for humanized rabbit cathepsin K to IC50 for rabbit cathepsin K	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID314222	Inhibition of cathepsin S	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314252	Inhibition of MHC 2 invariant chain iip10 in mouse splenocytes	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID458227	Selectivity ratio of IC50 for human cathepsin S to IC50 for humanized rabbit cathepsin K	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 ISSN: 1464-3405	The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
AID314228	Inhibition of human cathepsin K	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314236	Metabolic stability in rhesus monkey hepatocyte at 20 uM after 2 hrs assessed as recovery of parent compound	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID482421	Selectivity for cathepsin K over cathepsin V	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID458223	Inhibition of humanized rabbit cathepsin K	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 ISSN: 1464-3405	The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
AID458226	Selectivity ratio of IC50 for human cathepsin L to IC50 for humanized rabbit cathepsin K	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 ISSN: 1464-3405	The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
AID482422	Selectivity for cathepsin K over cathepsin H	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID314227	Inhibition of cathepsin Z	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314240	Clearance in rat at 10 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID569575	Inhibition of humanized rabbit cathepsin K	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID367446	Metabolic stability in human hepatocytes assessed as compound remaining after 2 hrs	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
AID1918205	Inhibition of Cathepsin B (unknown origin) assessed as inhibition of AFC release using sequence RR labelled with AFC as substrate by fluorescence based analysis	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74ISSN: 1464-3391	Discovery of selective covalent cathepsin K inhibitors containing novel 4-cyanopyrimidine warhead based on quantum chemical calculations and binding mode analysis.
AID1512167	Lipophilicity, log Kw of compound by HPLC analysis	2019	Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22 ISSN: 1464-3391	Synthesis and structure-activity relationship of nitrile-based cruzain inhibitors incorporating a trifluoroethylamine-based P2 amide replacement.
AID314246	Volume of distribution at steady state in dog at 5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID569579	Selectivity ratio of IC50 for human cathepsin S to IC50 for human cathepsin K	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID1918204	Inhibition of Cathepsin S (unknown origin) assessed as inhibition of AFC release using sequence VVR labelled with AFC as substrate by fluorescence based analysis	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74ISSN: 1464-3391	Discovery of selective covalent cathepsin K inhibitors containing novel 4-cyanopyrimidine warhead based on quantum chemical calculations and binding mode analysis.
AID314226	Inhibition of cathepsin H	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID482441	Bioavailability in dog	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11 ISSN: 1520-4804	Emerging targets in osteoporosis disease modification.
AID569578	Selectivity ratio of IC50 for human cathepsin L to IC50 for human cathepsin K	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID314238	Metabolic stability in dog hepatocyte at 20 uM after 2 hrs assessed as recovery of parent compound	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID314248	Clearance in rhesus monkey at 5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID367442	Selectivity ratio of IC50 for human cathepsin B to IC50 for humanized rabbit cathepsin K	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
AID314249	Half life in rhesus monkey at 5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID569572	Half life in rat at 10 mg/kg, po or 2 mg/kg, iv	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 ISSN: 1464-3405	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3 ISSN: 1754-8411	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3 ISSN: 1754-8411	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345903	Human cathepsin K (C1: Papain)	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
AID1345894	Human cathepsin Z (C1: Papain)	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (6.80)	29.6817
2010's	115 (78.23)	24.3611
2020's	22 (14.97)	2.80

Publication Type	This drug (%)	All Drugs (%)
Trials	27 (18.24%)	5.53%
Reviews	38 (25.68%)	6.00%
Case Studies	1 (0.68%)	4.05%
Observational	0 (0.00%)	0.25%
Other	82 (55.41%)	84.16%

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's	post-2020
aminolevulinic acid	1	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite	2023	2023	1.0	low	0	0	1
coumarin	1	coumarins	fluorescent dye; human metabolite; plant metabolite	2023	2023	1.0	low	0	0	1
salicylic acid	1	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite	2023	2023	1.0	low	0	0	1
thioctic acid	1	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector	2023	2023	1.0	low	0	0	1
picolinic acid	1	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material	2023	2023	1.0	low	0	0	1
thiamine	1	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2023	2023	1.0	low	0	0	1
3-aminobenzamide	1	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
pleconaril	1			2023	2023	1.0	low	0	0	1
4-(2-aminoethyl)benzenesulfonylfluoride	1			2023	2023	1.0	low	0	0	1
phenytoin	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent	2023	2023	1.0	low	0	0	1
acetazolamide	1	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor	2023	2023	1.0	low	0	0	1
alprenolol	1	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	2023	2023	1.0	low	0	0	1
am 251	1	amidopiperidine; carbohydrazide; dichlorobenzene; organoiodine compound; pyrazoles	antidepressant; antineoplastic agent; apoptosis inducer; CB1 receptor antagonist	2010	2010	14.0	low	1	0	0
amantadine	1	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic	2023	2023	1.0	low	0	0	1
2-aminothiazole	1	1,3-thiazoles; primary amino compound		2023	2023	1.0	low	0	0	1
amodiaquine	1	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug	2023	2023	1.0	low	0	0	1
aspirin	1	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent	2023	2023	1.0	low	0	0	1
baclofen	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant	2023	2023	1.0	low	0	0	1
benzamide	1	benzamides		2023	2023	1.0	low	0	0	1
camostat	1	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor	2023	2023	1.0	low	0	0	1
camphor, (+-)-isomer	1	bornane monoterpenoid; cyclic monoterpene ketone	plant metabolite	2023	2023	1.0	low	0	0	1
candesartan	1	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
cetylpyridinium	1	pyridinium ion		2023	2023	1.0	low	0	0	1
chloroxylenol	1	monochlorobenzenes; phenols	antiseptic drug; disinfectant; molluscicide	2023	2023	1.0	low	0	0	1
chlorpromazine	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug	2023	2023	1.0	low	0	0	1
ciprofibrate	1	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug	2023	2023	1.0	low	0	0	1
clomipramine	1	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor	2023	2023	1.0	low	0	0	1
danthron	1	dihydroxyanthraquinone	apoptosis inducer; plant metabolite	2023	2023	1.0	low	0	0	1
deferiprone	1	4-pyridones	iron chelator; protective agent	2023	2023	1.0	low	0	0	1
dipyridamole	1	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent	2023	2023	1.0	low	0	0	1
disulfiram	1	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor	2023	2023	1.0	low	0	0	1
valproic acid	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent	2023	2023	1.0	low	0	0	1
doxazosin	1	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent	2023	2023	1.0	low	0	0	1
ebselen	1	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger	2023	2023	1.0	low	0	0	1
etidronate	1	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator	2023	2023	1.0	low	0	0	1
2-hexyloxybenzamide	1	aromatic ether; benzamides	antifungal agent	2023	2023	1.0	low	0	0	1
brl 42810	1	2-aminopurines; acetate ester	antiviral drug; prodrug	2023	2023	1.0	low	0	0	1
fluphenazine	1	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug	2023	2023	1.0	low	0	0	1
fluorouracil	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic	2023	2023	1.0	low	0	0	1
gabexate	1	benzoate ester		2023	2023	1.0	low	0	0	1
glutaral	1	dialdehyde	cross-linking reagent; disinfectant; fixative	2023	2023	1.0	low	0	0	1
fasudil	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	2023	2023	1.0	low	0	0	1
haloperidol	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist	2023	2023	1.0	low	0	0	1
miltefosine	1	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor	2023	2023	1.0	low	0	0	1
hexylresorcinol	1	resorcinols		2023	2023	1.0	low	0	0	1
beta-thujaplicin	1	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite	2023	2023	1.0	low	0	0	1
hycanthone	1	thioxanthenes	mutagen; schistosomicide drug	2023	2023	1.0	low	0	0	1
hydrochlorothiazide	1	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
hydroxyurea	1	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent	2023	2023	1.0	low	0	0	1
ibuprofen	1	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic	2023	2023	1.0	low	0	0	1
indomethacin	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic	2023	2023	1.0	low	0	0	1
avapro	1	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
itraconazole	1	piperazines		2023	2023	1.0	low	0	0	1
kojic acid	1	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent	2023	2023	1.0	low	0	0	1
lapachol	1			2023	2023	1.0	low	0	0	1
loperamide	1	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist	2023	2023	1.0	low	0	0	1
loratadine	1	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist	2023	2023	1.0	low	0	0	1
losartan	1	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist	2023	2023	1.0	low	0	0	1
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide	1	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	1
mafenide	1	aromatic amine		2023	2023	1.0	low	0	0	1
methazolamide	1	sulfonamide; thiadiazoles		2023	2023	1.0	low	0	0	1
methocarbamol	1	aromatic ether; carbamate ester; secondary alcohol		2023	2023	1.0	low	0	0	1
mitoxantrone	1	dihydroxyanthraquinone	analgesic; antineoplastic agent	2023	2023	1.0	low	0	0	1
entinostat	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	1
ethylmaleimide	1	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor	2023	2023	1.0	low	0	0	1
nabumetone	1	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug	2023	2023	1.0	low	0	0	1
nafamostat	1	benzoic acids; guanidines		2023	2023	1.0	low	0	0	1
nevirapine	1	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
omeprazole	1	aromatic ether; benzimidazoles; pyridines; sulfoxide		2023	2023	1.0	low	0	0	1
osalmide	1	organic molecular entity		2023	2023	1.0	low	0	0	1
oxethazaine	1	amino acid amide		2023	2023	1.0	low	0	0	1
palmidrol	1	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent	2023	2023	1.0	low	0	0	1
papaverine	1	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent	2023	2023	1.0	low	0	0	1
pentoxifylline	1	oxopurine		2023	2023	1.0	low	0	0	1
perhexiline	1	piperidines	cardiovascular drug	2023	2023	1.0	low	0	0	1
phenazopyridine	1	diaminopyridine; monoazo compound	anticoronaviral agent; carcinogenic agent; local anaesthetic; non-narcotic analgesic	2023	2023	1.0	low	0	0	1
4-phenylbutyric acid	1	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug	2023	2023	1.0	low	0	0	1
phenylmethylsulfonyl fluoride	1	acyl fluoride	serine proteinase inhibitor	2023	2023	1.0	low	0	0	1
pimobendan	1	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent	2023	2023	1.0	low	0	0	1
pj-34	1	phenanthridines; secondary carboxamide; tertiary amino compound	angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent	2023	2023	1.0	low	0	0	1
praziquantel	1	isoquinolines		2023	2023	1.0	low	0	0	1
probenecid	1	benzoic acids; sulfonamide	uricosuric drug	2023	2023	1.0	low	0	0	1
probucol	1	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug	2023	2023	1.0	low	0	0	1
promazine	1	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist	2023	2023	1.0	low	0	0	1
promethazine	1	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative	2023	2023	1.0	low	0	0	1
propranolol	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic	2023	2023	1.0	low	0	0	1
rimantadine	1	alkylamine		2023	2023	1.0	low	0	0	1
rolipram	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor	2023	2023	1.0	low	0	0	1
scriptaid	1	isoquinolines		2023	2023	1.0	low	0	0	1
sebacic acid	1	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	human metabolite; plant metabolite	2023	2023	1.0	low	0	0	1
fenofibrate	1	benzochromenone; delta-lactone; naphtho-alpha-pyrone	platelet aggregation inhibitor; Sir2 inhibitor	2023	2023	1.0	low	0	0	1
imatinib	1	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	2023	2023	1.0	low	0	0	1
suprofen	1	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug	2023	2023	1.0	low	0	0	1
thalidomide	1	phthalimides; piperidones		2023	2023	1.0	low	0	0	1
ticlopidine	1	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor	2023	2023	1.0	low	0	0	1
triamterene	1	pteridines	diuretic; sodium channel blocker	2023	2023	1.0	low	0	0	1
trifluoperazine	1	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug	2023	2023	1.0	low	0	0	1
triflupromazine	1	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic	2023	2023	1.0	low	0	0	1
trigonelline	1	alkaloid; iminium betaine	food component; human urinary metabolite; plant metabolite	2023	2023	1.0	low	0	0	1
trimethobenzamide	1	benzamides; tertiary amino compound	antiemetic	2023	2023	1.0	low	0	0	1
trimethoprim	1	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
tyrphostin a9	1	alkylbenzene	geroprotector	2023	2023	1.0	low	0	0	1
delavirdine	1	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
vesnarinone	1	organic molecular entity		2023	2023	1.0	low	0	0	1
idoxuridine	1	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor	2023	2023	1.0	low	0	0	1
chloramphenicol	1	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
lysine	1	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite	2023	2023	1.0	low	0	0	1
phenylethyl alcohol	1	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite	2023	2023	1.0	low	0	0	1
zoxazolamine	1	benzoxazole		2023	2023	1.0	low	0	0	1
cycloheximide	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
ficusin	1	psoralens	plant metabolite	2023	2023	1.0	low	0	0	1
tubercidin	1	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite	2023	2023	1.0	low	0	0	1
trifluridine	1	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor	2023	2023	1.0	low	0	0	1
9,10-anthraquinone	1	anthraquinone		2023	2023	1.0	low	0	0	1
salicylanilide	1	benzanilide fungicide; salicylamides; salicylanilides		2023	2023	1.0	low	0	0	1
gramine	1	aminoalkylindole; indole alkaloid; tertiary amino compound	antibacterial agent; antiviral agent; plant metabolite; serotonergic antagonist	2023	2023	1.0	low	0	0	1
aminacrine	1	aminoacridines; primary amino compound	acid-base indicator; antiinfective agent; antiseptic drug; fluorescent dye; MALDI matrix material; mutagen	2023	2023	1.0	low	0	0	1
methyl gallate	1	gallate ester	anti-inflammatory agent; antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
monobenzone	1	benzyl ether	allergen; dermatologic drug; melanin synthesis inhibitor	2023	2023	1.0	low	0	0	1
ditiocarb	1	dithiocarbamic acids	chelator; copper chelator	2023	2023	1.0	low	0	0	1
catechin	1	catechin	antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
azacitidine	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent	2023	2023	1.0	low	0	0	1
lucanthone	1	thioxanthenes	adjuvant; antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; mutagen; photosensitizing agent; prodrug; schistosomicide drug	2023	2023	1.0	low	0	0	1
cepharanthine	1	bisbenzylisoquinoline alkaloid; isoquinolines		2023	2023	1.0	low	0	0	1
aloe emodin	1	aromatic primary alcohol; dihydroxyanthraquinone	antineoplastic agent; plant metabolite	2023	2023	1.0	low	0	0	1
chrysophanic acid	1	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite	2023	2023	1.0	low	0	0	1
emetine	1	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
osthol	1	botanical anti-fungal agent; coumarins	metabolite	2023	2023	1.0	low	0	0	1
flavanone	1	flavanones		2023	2023	1.0	low	0	0	1
phloretic acid	1	hydroxy monocarboxylic acid	plant metabolite	2023	2023	1.0	low	0	0	1
oleanolic acid	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite	2023	2023	1.0	low	0	0	1
angelicin	1	furanocoumarin		2023	2023	1.0	low	0	0	1
diperodon	1	carbamate ester		2023	2023	1.0	low	0	0	1
megestrol acetate	1	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive	2023	2023	1.0	low	0	0	1
acetylcysteine	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary	2023	2023	1.0	low	0	0	1
hydroxychloroquine sulfate	1			2023	2023	1.0	low	0	0	1
ethambutol	1	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
metformin hydrochloride	1	hydrochloride	environmental contaminant; hypoglycemic agent; xenobiotic	2023	2023	1.0	low	0	0	1
antimycin a	1	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide	2023	2023	1.0	low	0	0	1
5,5'-dimethyl-2,2'-bipyridyl	1	bipyridines		2023	2023	1.0	medium	0	0	1
dichlorobenzyl alcohol	1	benzyl alcohols; dichlorobenzene	antiseptic drug	2023	2023	1.0	low	0	0	1
stavudine	1	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2023	2023	1.0	low	0	0	1
dideoxyadenosine	1	adenosines; purine 2',3'-dideoxyribonucleoside	EC 3.5.4.4 (adenosine deaminase) inhibitor; EC 4.6.1.1 (adenylate cyclase) inhibitor	2023	2023	1.0	low	0	0	1
vidarabine	1	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic	2023	2023	1.0	low	0	0	1
3-deazaadenosine	1			2023	2023	1.0	low	0	0	1
zalcitabine	1	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
ancitabine	1	diol; organic heterotricyclic compound	antimetabolite; antineoplastic agent; prodrug	2023	2023	1.0	low	0	0	1
chloropyramine	1	aminopyridine		2023	2023	1.0	low	0	0	1
levamisole	1	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator	2023	2023	1.0	low	0	0	1
n'-nitrosonornicotine	1	pyridines; pyrrolidines		2023	2023	1.0	low	0	0	1
daunorubicin	1	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite	2023	2023	1.0	low	0	0	1
zidovudine	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
ribavirin	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2023	2023	1.0	low	0	0	1
pyridoxal phosphate	1	pyridinecarbaldehyde		2023	2023	1.0	medium	0	0	1
nitazoxanide	1	benzamides; carboxylic ester		2023	2023	1.0	low	0	0	1
captopril	1	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	2023	2023	1.0	low	0	0	1
oltipraz	1	1,2-dithiole; pyrazines	angiogenesis modulating agent; antimutagen; antineoplastic agent; antioxidant; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; neurotoxin; protective agent; schistosomicide drug	2023	2023	1.0	low	0	0	1
fiacitabine	1			2023	2023	1.0	low	0	0	1
ranolazine	1	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol		2023	2023	1.0	low	0	0	1
brequinar	1	biphenyls; monocarboxylic acid; monofluorobenzenes; quinolinemonocarboxylic acid	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor	2023	2023	1.0	low	0	0	1
imiquimod	1	imidazoquinoline	antineoplastic agent; interferon inducer	2023	2023	1.0	low	0	0	1
adefovir	1	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent	2023	2023	1.0	low	0	0	1
cidofovir anhydrous	1	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent	2023	2023	1.0	low	0	0	1
celgosivir	1			2023	2023	1.0	low	0	0	1
gemcitabine	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic	2023	2023	1.0	low	0	0	1
lamivudine	1	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug	2023	2023	1.0	low	0	0	1
valsartan	1	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
zanamivir	1	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor	2023	2023	1.0	low	0	0	1
adefovir dipivoxil	1	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug	2023	2023	1.0	low	0	0	1
emtricitabine	1	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
octyl gallate	1	gallate ester	food antioxidant; hypoglycemic agent; plant metabolite	2023	2023	1.0	low	0	0	1
efavirenz	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
nelfinavir	1	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
betulinic acid	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite	2023	2023	1.0	low	0	0	1
arctigenin	1	lignan		2023	2023	1.0	low	0	0	1
baicalin	1	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug	2023	2023	1.0	low	0	0	1
plerixafor	1	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant	2023	2023	1.0	low	0	0	1
amprenavir	1	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
oseltamivir	1	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic	2023	2023	1.0	low	0	0	1
epigallocatechin gallate	2	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite	2010	2023	7.5	low	1	0	1
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose	1	gallate ester; galloyl beta-D-glucose	anti-inflammatory agent; antineoplastic agent; geroprotector; hepatoprotective agent; plant metabolite; radiation protective agent; radical scavenger	2023	2023	1.0	low	0	0	1
cephalotaxine	1	benzazepine alkaloid fundamental parent; benzazepine alkaloid; cyclic acetal; enol ether; organic heteropentacyclic compound; secondary alcohol; tertiary amino compound		2023	2023	1.0	medium	0	0	1
desipramine hydrochloride	1	hydrochloride	drug allergen	2023	2023	1.0	low	0	0	1
mefloquine hydrochloride	1	hydrochloride		2023	2023	1.0	low	0	0	1
aloxistatin	1	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor	2023	2023	1.0	low	0	0	1
propazole	1	benzimidazoles		2023	2023	1.0	low	0	0	1
prulifloxacin	1	fluoroquinolone antibiotic; quinolone antibiotic		2023	2023	1.0	low	0	0	1
telmisartan	1	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
bergenin	1	trihydroxybenzoic acid	metabolite	2023	2023	1.0	low	0	0	1
zoledronic acid	1	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent	2023	2023	1.0	low	0	0	1
artemisinin	1	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite	2023	2023	1.0	low	0	0	1
brinzolamide	1	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor	2023	2023	1.0	low	0	0	1
dipropylacetamide	1	fatty amide	geroprotector; metabolite; teratogenic agent	2023	2023	1.0	low	0	0	1
oxprenolol hydrochloride	1			2023	2023	1.0	low	0	0	1
opipramol hydrochloride	1			2023	2023	1.0	low	0	0	1
moroxydine	1	biguanides		2023	2023	1.0	low	0	0	1
thioxolone	1	benzoxathiole	antiseborrheic	2023	2023	1.0	low	0	0	1
honokiol	1	biphenyls		2023	2023	1.0	low	0	0	1
nobiletin	1	methoxyflavone	antineoplastic agent; plant metabolite	2023	2023	1.0	low	0	0	1
lycorine	1	indolizidine alkaloid	anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
leupeptin	1	aldehyde; tripeptide	bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor	2023	2023	1.0	low	0	0	1
tetrandrine	1	bisbenzylisoquinoline alkaloid; isoquinolines		2023	2023	1.0	low	0	0	1
calpeptin	1	amino acid amide		2023	2023	1.0	low	0	0	1
fangchinoline	1	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
maslinic acid	1	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
atovaquone	1	hydroxy-1,2-naphthoquinone		2023	2023	1.0	low	0	0	1
loganin	1	beta-D-glucoside; cyclopentapyran; enoate ester; iridoid monoterpenoid; methyl ester; monosaccharide derivative; secondary alcohol	anti-inflammatory agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.4.23.46 (memapsin 2) inhibitor; neuroprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
moexipril	1	peptide		2023	2023	1.0	low	0	0	1
aucubin	1	organic molecular entity	metabolite	2023	2023	1.0	low	0	0	1
catalpol	1	organic molecular entity	metabolite	2023	2023	1.0	low	0	0	1
lekoptin	1	2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile		2023	2023	1.0	low	0	0	1
n-methyladenosine	1	methyladenosine		2023	2023	1.0	low	0	0	1
cp-55,940	1			2010	2010	14.0	low	1	0	0
sivelestat	1	N-acylglycine; pivalate ester		2023	2023	1.0	low	0	0	1
pyronaridine	1	aminoquinoline		2023	2023	1.0	low	0	0	1
geniposide	1	terpene glycoside		2023	2023	1.0	low	0	0	1
daidzin	1	7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative	plant metabolite	2023	2023	1.0	low	0	0	1
sophocarpine	1			2023	2023	1.0	low	0	0	1
marimastat	1	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor	2023	2023	1.0	low	0	0	1
elacridar	1			2023	2023	1.0	low	0	0	1
celastrol	1	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite	2023	2023	1.0	low	0	0	1
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine	1	leucine derivative		2023	2023	1.0	low	0	0	1
vadimezan	1	monocarboxylic acid; xanthones	antineoplastic agent	2023	2023	1.0	low	0	0	1
e 64	1	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor	2023	2023	1.0	low	0	0	1
umifenovir	1	indolyl carboxylic acid		2023	2023	1.0	low	0	0	1
safinamide	1	amino acid amide		2023	2023	1.0	low	0	0	1
ilomastat	1	hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid	anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent	2023	2023	1.0	low	0	0	1
atazanavir	1	carbohydrazide	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
vx 497	1			2023	2023	1.0	low	0	0	1
bcx 1812	1	3-hydroxy monocarboxylic acid; acetamides; cyclopentanols; guanidines	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor	2023	2023	1.0	low	0	0	1
naproxen	1	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	2023	2023	1.0	low	0	0	1
olmesartan	1	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent	2023	2023	1.0	low	0	0	1
telbivudine	1	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2023	2023	1.0	low	0	0	1
celastrol methyl ester	1	carboxylic ester		2023	2023	1.0	low	0	0	1
resiquimod	1	imidazoquinoline		2023	2023	1.0	low	0	0	1
tanshinone ii a	1	abietane diterpenoid		2023	2023	1.0	low	0	0	1
anacardic acid	1	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
migalastat	1	piperidines		2023	2023	1.0	low	0	0	1
erlotinib	1	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor	2023	2023	1.0	low	0	0	1
cilengitide	1	oligopeptide		2010	2010	14.0	low	1	0	0
limonin	1	epoxide; furans; hexacyclic triterpenoid; lactone; limonoid; organic heterohexacyclic compound	inhibitor; metabolite; volatile oil component	2023	2023	1.0	low	0	0	1
scutellarin	1	glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antineoplastic agent; proteasome inhibitor	2023	2023	1.0	low	0	0	1
etravirine	1	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
chelidonine	1	alkaloid antibiotic; alkaloid fundamental parent; benzophenanthridine alkaloid		2023	2023	1.0	low	0	0	1
4-n-butylresorcinol	1	resorcinols		2023	2023	1.0	low	0	0	1
darunavir	1	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
dapivirine	1			2023	2023	1.0	low	0	0	1
nsc 74859	1	amidobenzoic acid; monohydroxybenzoic acid; tosylate ester	STAT3 inhibitor	2023	2023	1.0	low	0	0	1
berbamine	1	bisbenzylisoquinoline alkaloid; isoquinolines		2023	2023	1.0	low	0	0	1
u-104	1			2023	2023	1.0	low	0	0	1
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one	1	glycoside		2023	2023	1.0	medium	0	0	1
bortezomib	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor	2023	2023	1.0	low	0	0	1
ritonavir	1	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic	2023	2023	1.0	low	0	0	1
tizoxanide	1	salicylamides		2023	2023	1.0	low	0	0	1
arbutin	1	beta-D-glucoside; monosaccharide derivative	Escherichia coli metabolite; plant metabolite	2023	2023	1.0	low	0	0	1
quinidine	1	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker	2023	2023	1.0	low	0	0	1
conessine	1	steroid alkaloid; tertiary amino compound	antibacterial agent; antimalarial; H3-receptor antagonist; plant metabolite	2023	2023	1.0	low	0	0	1
saquinavir	1	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
abacavir	1	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
linezolid	1	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
cephaelin	1	pyridoisoquinoline		2023	2023	1.0	low	0	0	1
naringin	1	(2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; disaccharide derivative; neohesperidoside	anti-inflammatory agent; antineoplastic agent; metabolite	2010	2010	14.0	low	1	0	0
(-)-usnic acid	1	usnic acid	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor	2023	2023	1.0	medium	0	0	1
acetylleucyl-leucyl-norleucinal	1	aldehyde; tripeptide	cysteine protease inhibitor	2023	2023	1.0	low	0	0	1
resveratrol	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger	2023	2023	1.0	low	0	0	1
tacrolimus	1	macrolide lactam	bacterial metabolite; immunosuppressive agent	2023	2023	1.0	low	0	0	1
lycopene	1	acyclic carotene	antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
zithromax	1	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
roflumilast	1	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor	2023	2023	1.0	low	0	0	1
L-cycloserine	1	4-amino-1,2-oxazolidin-3-one	anti-HIV agent; anticonvulsant; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
h 89	1	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide		2023	2023	1.0	low	0	0	1
bevirimat	1	dicarboxylic acid monoester; monocarboxylic acid; pentacyclic triterpenoid	HIV-1 maturation inhibitor; metabolite	2023	2023	1.0	low	0	0	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	1	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor	2023	2023	1.0	low	0	0	1
tenofovir	1	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
posaconazole	1	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug	2023	2023	1.0	low	0	0	1
gw 257406x	1			2023	2023	1.0	low	0	0	1
shikonin	1	hydroxy-1,4-naphthoquinone		2023	2023	1.0	low	0	0	1
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide	1	tropane alkaloid		2023	2023	1.0	medium	0	0	1
cmx 001	1			2023	2023	1.0	low	0	0	1
amd 8664	1			2023	2023	1.0	medium	0	0	1
bay 41-4109	1			2023	2023	1.0	low	0	0	1
bay 57-1293	1			2023	2023	1.0	low	0	0	1
2'-c-methylcytidine	1			2023	2023	1.0	low	0	0	1
isoxanthohumol	1	flavanones		2023	2023	1.0	low	0	0	1
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide	1	aromatic ether		2023	2023	1.0	low	0	0	1
mecarbinate	1			2023	2023	1.0	low	0	0	1
cannabidiol	1	olefinic compound; phytocannabinoid; resorcinols	antimicrobial agent; plant metabolite	2010	2010	14.0	low	1	0	0
acetyl-aspartyl-glutamyl-valyl-aspartal	1	tetrapeptide	protease inhibitor	2023	2023	1.0	low	0	0	1
octotropine methylbromide	1			2023	2023	1.0	low	0	0	1
mercaptopurine	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent	2023	2023	1.0	low	0	0	1
jrf 12	1			2023	2023	1.0	low	0	0	1
3,4'-dihydroxyflavone	1			2023	2023	1.0	medium	0	0	1
3-(3,4-dimethoxyphenyl)propenoic acid	1	methoxycinnamic acid		2023	2023	1.0	low	0	0	1
isoferulic acid	1	ferulic acids	antioxidant; biomarker; metabolite	2023	2023	1.0	low	0	0	1
cyclouridine	1			2023	2023	1.0	medium	0	0	1
curcumin	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger	2023	2023	1.0	low	0	0	1
zucapsaicin	1	methoxybenzenes; phenols		2023	2023	1.0	low	0	0	1
nbd 556	1			2023	2023	1.0	low	0	0	1
thioguanine anhydrous	1	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent	2023	2023	1.0	low	0	0	1
4,5,6,7-tetrachloroindan-1,3-dione	1			2023	2023	1.0	high	0	0	1
srpin340	1			2023	2023	1.0	low	0	0	1
pr-619	1			2023	2023	1.0	medium	0	0	1
p5091	1			2023	2023	1.0	low	0	0	1
trovirdine	1			2023	2023	1.0	low	0	0	1
fti 277	1			2023	2023	1.0	high	0	0	1
u 0126	1	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent	2023	2023	1.0	low	0	0	1
vicriviroc	1	(trifluoromethyl)benzenes		2023	2023	1.0	low	0	0	1
telaprevir	1	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic	2023	2023	1.0	low	0	0	1
orlistat	1	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor	2023	2023	1.0	low	0	0	1
dasatinib	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2023	2023	1.0	low	0	0	1
yya-021	1			2023	2023	1.0	medium	0	0	1
sb 415286	1	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	2023	2023	1.0	low	0	0	1
am 630	1	N-acylindole		2010	2010	14.0	low	1	0	0
sitagliptin	1	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic	2023	2023	1.0	low	0	0	1
tak-220	1			2023	2023	1.0	medium	0	0	1
jtk-303	1	aromatic ether; monochlorobenzenes; organofluorine compound; quinolinemonocarboxylic acid; quinolone	HIV-1 integrase inhibitor	2023	2023	1.0	low	0	0	1
nbd 557	1			2023	2023	1.0	medium	0	0	1
dinoprostone	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic	2010	2010	14.0	low	1	0	0
5'-o-caffeoylquinic acid	1	cinnamate ester; cyclitol carboxylic acid	plant metabolite	2023	2023	1.0	medium	0	0	1
luteolin-7-glucoside	1	beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
cyclosporine	1			2023	2023	1.0	low	0	0	1
harmine	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite	2023	2023	1.0	low	0	0	1
eprosartan	1	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
mycophenolate mofetil	1	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug	2023	2023	1.0	low	0	0	1
entacapone	1	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
amentoflavone	1	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite	2023	2023	1.0	low	0	0	1
baicalein	1	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger	2023	2023	1.0	low	0	0	1
genkwanin	1	dihydroxyflavone; monomethoxyflavone	metabolite	2023	2023	1.0	low	0	0	1
hyperoside	1	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
mangostin	1	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
3-methylquercetin	1	7-hydroxyflavonol; monomethoxyflavone; tetrahydroxyflavone	anticoagulant; EC 1.14.18.1 (tyrosinase) inhibitor; metabolite	2023	2023	1.0	low	0	0	1
kaempferide	1	7-hydroxyflavonol; monomethoxyflavone; trihydroxyflavone	antihypertensive agent; metabolite	2023	2023	1.0	low	0	0	1
orientin	1	3'-hydroxyflavonoid; C-glycosyl compound; tetrahydroxyflavone	antioxidant; metabolite	2023	2023	1.0	low	0	0	1
sciadopitysin	1	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	bone density conservation agent; platelet aggregation inhibitor	2010	2010	14.0	low	1	0	0
scutellarein	1	tetrahydroxyflavone	metabolite	2023	2023	1.0	low	0	0	1
trans-2,3',4,5'-tetrahydroxystilbene	1	stilbenoid		2023	2023	1.0	low	0	0	1
polydatin	1	beta-D-glucoside; monosaccharide derivative; polyphenol; stilbenoid	anti-arrhythmia drug; antioxidant; geroprotector; hepatoprotective agent; metabolite; nephroprotective agent; potassium channel modulator	2023	2023	1.0	low	0	0	1
chicoric acid	1	organooxygen compound	geroprotector; HIV-1 integrase inhibitor	2023	2023	1.0	low	0	0	1
acteoside	1	catechols; cinnamate ester; disaccharide derivative; glycoside; polyphenol	anti-inflammatory agent; antibacterial agent; antileishmanial agent; neuroprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
dorzolamide	1	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor	2023	2023	1.0	low	0	0	1
topiramate	1	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker	2023	2023	1.0	low	0	0	1
benzyloxycarbonyl-phe-ala-fluormethylketone	1			2023	2023	1.0	high	0	0	1
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester	1	carboxylic ester; difluorobenzene; dipeptide; tert-butyl ester	EC 3.4.23.46 (memapsin 2) inhibitor	2023	2023	1.0	low	0	0	1
casticin	1	dihydroxyflavone; tetramethoxyflavone	apoptosis inducer; plant metabolite	2023	2023	1.0	low	0	0	1
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	1	dihydroxyflavone; monomethoxyflavone	antineoplastic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor	2023	2023	1.0	low	0	0	1
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside	1	beta-D-glucoside; resorcinols; stilbenoid	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; cyclooxygenase 2 inhibitor; platelet aggregation inhibitor	2023	2023	1.0	low	0	0	1
tyrphostin ag 555	1			2023	2023	1.0	low	0	0	1
pd 151746	1			2023	2023	1.0	medium	0	0	1
lisinopril	1	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	2023	2023	1.0	low	0	0	1
verteporfin	1			2023	2023	1.0	low	0	0	1
batimastat	1	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor	2023	2023	1.0	low	0	0	1
indinavir sulfate	1	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor	2023	2023	1.0	low	0	0	1
solanesol	1	nonaprenol; primary alcohol	plant metabolite	2023	2023	1.0	low	0	0	1
pepstatin	1	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor	2023	2023	1.0	low	0	0	1
l 685458	1	carbamate ester; monocarboxylic acid amide; peptide; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor; peptidomimetic	2023	2023	1.0	low	0	0	1
bms 806	1			2023	2023	1.0	low	0	0	1
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	1			2023	2023	1.0	medium	0	0	1
tulobuterol hydrochloride	1	organic molecular entity		2023	2023	1.0	low	0	0	1
salubrinal	1	aminal; organochlorine compound; quinolines; secondary carboxamide; thioureas		2023	2023	1.0	low	0	0	1
germacrone	1	germacrane sesquiterpenoid; olefinic compound	androgen antagonist; anti-inflammatory agent; antifeedant; antifungal agent; antimicrobial agent; antineoplastic agent; antioxidant; antitussive; antiviral agent; apoptosis inducer; autophagy inducer; hepatoprotective agent; insecticide; neuroprotective agent; plant metabolite; volatile oil component	2023	2023	1.0	low	0	0	1
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid	1			2023	2023	1.0	low	0	0	1
lithospermic acid	1			2023	2023	1.0	medium	0	0	1
laq824	1			2023	2023	1.0	low	0	0	1
ekb 569	1	aminoquinoline; monocarboxylic acid amide; monochlorobenzenes; nitrile	protein kinase inhibitor	2023	2023	1.0	low	0	0	1
rilpivirine	1	aminopyrimidine; nitrile	EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one	1	germacranolide		2023	2023	1.0	medium	0	0	1
4,5-di-O-caffeoylquinic acid	1	quinic acid		2023	2023	1.0	low	0	0	1
indigo carmine	1			2023	2023	1.0	low	0	0	1
artesunate	1	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer	2023	2023	1.0	low	0	0	1
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	1	oligopeptide		2023	2023	1.0	low	0	0	1
nps2143	1			2010	2010	14.0	low	1	0	0
jwh-133	1	benzochromene; dibenzopyran; organic heterotricyclic compound	analgesic; anti-inflammatory agent; antineoplastic agent; apoptosis inhibitor; CB2 receptor agonist; opioid analgesic; vasodilator agent	2010	2010	14.0	low	1	0	0
vildagliptin	1	amino acid amide		2023	2023	1.0	low	0	0	1
relacatib	2			2008	2010	15.0	high	2	0	0
belinostat	1	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	1
hdac-42	1	amidobenzoic acid		2023	2023	1.0	low	0	0	1
chlorhexidine	1	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent	2023	2023	1.0	low	0	0	1
gs-7340	1	6-aminopurines; ether; isopropyl ester; L-alanine derivative; phosphoramidate ester	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug	2023	2023	1.0	low	0	0	1
iniparib	1	carbonyl compound; organohalogen compound		2023	2023	1.0	low	0	0	1
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide	1			2023	2023	1.0	low	0	0	1
pri-2205	1			2023	2023	1.0	low	0	0	1
mk 0752	1			2023	2023	1.0	low	0	0	1
ono4819	1	benzyl ether		2010	2010	14.0	low	1	0	0
givinostat	1	carbamate ester		2023	2023	1.0	low	0	0	1
pd 144418	1			2023	2023	1.0	medium	0	0	1
ca 074	1			2018	2018	6.0	medium	0	1	0
bicyclol	1			2023	2023	1.0	low	0	0	1
midostaurin	1	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2023	2023	1.0	low	0	0	1
ly 450139	1	peptide		2023	2023	1.0	low	0	0	1
mk-0429	1			2010	2010	14.0	medium	1	0	0
mocetinostat	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent	2023	2023	1.0	low	0	0	1
rivaroxaban	1	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor	2023	2023	1.0	low	0	0	1
sb 3ct compound	1	aromatic ether		2023	2023	1.0	low	0	0	1
ginsenoside rb1	1	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger	2023	2023	1.0	low	0	0	1
l-873724	2			2008	2011	14.5	medium	1	1	0
rucaparib	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-	1	organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2023	2023	1.0	low	0	0	1
cetilistat	1	benzoxazine		2023	2023	1.0	low	0	0	1
ym 201636	1	aromatic amide		2023	2023	1.0	low	0	0	1
linagliptin	1	aminopiperidine; quinazolines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent	2023	2023	1.0	low	0	0	1
azd 6244	1	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2023	2023	1.0	low	0	0	1
apilimod	1			2023	2023	1.0	low	0	0	1
apixaban	1	aromatic ether; lactam; piperidones; pyrazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor	2023	2023	1.0	low	0	0	1
balicatib	4			2008	2012	13.5	medium	2	2	0
betrixaban	1	benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor	2023	2023	1.0	low	0	0	1
edoxaban	1	chloropyridine; monocarboxylic acid amide; tertiary amino compound; thiazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor; platelet aggregation inhibitor	2023	2023	1.0	low	0	0	1
saracatinib	2	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent	2010	2023	7.5	low	1	0	1
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	1	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic	2023	2023	1.0	low	0	0	1
ly 411575	1	dibenzoazepine; difluorobenzene; lactam; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor	2023	2023	1.0	low	0	0	1
galidesivir	1			2023	2023	1.0	low	0	0	1
PB28	1	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist	2023	2023	1.0	low	0	0	1
degrasyn	1			2023	2023	1.0	low	0	0	1
epoxomicin	1	morpholines; tripeptide	proteasome inhibitor	2023	2023	1.0	low	0	0	1
bms 477118	1	adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent	2023	2023	1.0	low	0	0	1
pha 680632	1			2023	2023	1.0	low	0	0	1
tmc 353121	1			2023	2023	1.0	medium	0	0	1
amd 070	1	aminoquinoline		2023	2023	1.0	low	0	0	1
danoprevir	1			2023	2023	1.0	low	0	0	1
bms-626529	1			2023	2023	1.0	low	0	0	1
bms-663068	1			2023	2023	1.0	low	0	0	1
amenamevir	1			2023	2023	1.0	low	0	0	1
vx 765	1	dipeptide		2023	2023	1.0	low	0	0	1
Dihydrotanshinone I	1	abietane diterpenoid	anticoronaviral agent	2023	2023	1.0	low	0	0	1
alogliptin	1	nitrile; piperidines; primary amino compound; pyrimidines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent	2023	2023	1.0	low	0	0	1
fr 180204	1	pyrazoles; ring assembly		2023	2023	1.0	low	0	0	1
quisinostat	1	indoles		2023	2023	1.0	low	0	0	1
carfilzomib	1	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor	2023	2023	1.0	low	0	0	1
hcv 796	1			2023	2023	1.0	low	0	0	1
N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide	1	sulfonamide		2010	2010	14.0	medium	1	0	0
resminostat	1			2023	2023	1.0	low	0	0	1
zk 756326	1	aromatic ether		2023	2023	1.0	medium	0	0	1
balapiravir	1			2023	2023	1.0	low	0	0	1
trametinib	1	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2023	2023	1.0	low	0	0	1
pf-562,271	1	indoles		2010	2010	14.0	low	1	0	0
deoxyarbutin	1			2023	2023	1.0	low	0	0	1
abexinostat	1	benzofurans		2023	2023	1.0	low	0	0	1
silvestrol	1	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite	2023	2023	1.0	low	0	0	1
narlaprevir	1	azabicyclohexane; cyclopropanes; pyrrolidinecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide; ureas	anticoronaviral agent; antiviral drug; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; hepatitis C protease inhibitor	2023	2023	1.0	low	0	0	1
teneligliptin	1	amino acid amide		2023	2023	1.0	medium	0	0	1
dextrothyroxine	1			2023	2023	1.0	low	0	0	1
veliparib	1	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
pf 03491390	1			2023	2023	1.0	low	0	0	1
alloin	1	anthracenes; C-glycosyl compound; cyclic ketone; phenols	laxative; metabolite	2023	2023	1.0	high	0	0	1
mdv 3100	1	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent	2023	2023	1.0	low	0	0	1
bms-650032	1	oligopeptide		2023	2023	1.0	low	0	0	1
rg 7128	1			2023	2023	1.0	low	0	0	1
teriparatide	1	polypeptide		2010	2010	14.0	medium	1	0	0
oritavancin	1	disaccharide derivative; glycopeptide; semisynthetic derivative	antibacterial drug; antimicrobial agent	2023	2023	1.0	low	0	0	1
pevonedistat	1	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer	2023	2023	1.0	low	0	0	1
WAY-316606	1	(trifluoromethyl)benzenes; piperidines; secondary amino compound; sulfonamide; sulfone	secreted frizzled-related protein 1 inhibitor	2010	2010	14.0	high	1	0	0
uk 453,061	1	aromatic ether		2023	2023	1.0	low	0	0	1
N-(2-aminophenyl)-2-pyrazinecarboxamide	1	aromatic amide		2023	2023	1.0	high	0	0	1
tegobuvir	1			2023	2023	1.0	low	0	0	1
pf-429242	1			2023	2023	1.0	low	0	0	1
olaparib	1	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
cx 4945	1			2023	2023	1.0	low	0	0	1
pci 34051	1	indolecarboxamide		2023	2023	1.0	low	0	0	1
lomibuvir	1	thiophenecarboxylic acid		2023	2023	1.0	low	0	0	1
delanzomib	1	C-terminal boronic acid peptide; phenylpyridine; secondary alcohol; threonine derivative	antineoplastic agent; apoptosis inducer; proteasome inhibitor	2023	2023	1.0	low	0	0	1
pitavastatin(1-)	1	hydroxy monocarboxylic acid anion		2023	2023	1.0	high	0	0	1
GRL-0617	1	benzamides; naphthalenes; secondary carboxamide; substituted aniline	anticoronaviral agent; protease inhibitor	2023	2023	1.0	low	0	0	1
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester	1	carbamate ester		2023	2023	1.0	low	0	0	1
niraparib	1	2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent	2023	2023	1.0	low	0	0	1
jzl 184	1	benzodioxoles		2023	2023	1.0	low	0	0	1
gsk 650394	1	phenylpyridine		2023	2023	1.0	low	0	0	1
oprozomib	1			2023	2023	1.0	low	0	0	1
az 960	1			2023	2023	1.0	low	0	0	1
vel-0230	1			2010	2010	14.0	high	1	0	0
golgicide a	1	diastereoisomeric mixture	cis-Golgi ArfGEF GBF inhibitor	2023	2023	1.0	low	0	0	1
cobicistat	1	1,3-thiazoles; carbamate ester; monocarboxylic acid amide; morpholines; ureas	P450 inhibitor	2023	2023	1.0	low	0	0	1
bms-790052	1	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor	2023	2023	1.0	low	0	0	1
ixazomib	1	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor	2023	2023	1.0	low	0	0	1
ucph 101	1			2023	2023	1.0	low	0	0	1
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine	1	aryl sulfide; thienopyrimidine		2023	2023	1.0	low	0	0	1
baricitinib	1	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent	2023	2023	1.0	low	0	0	1
KOM70144	1	acetamides; benzamides; naphthalenes; secondary carboxamide	anticoronaviral agent; protease inhibitor	2023	2023	1.0	high	0	0	1
e-52862	1			2023	2023	1.0	low	0	0	1
ly2811376	1			2023	2023	1.0	low	0	0	1
anagliptin	1	amino acid amide		2023	2023	1.0	low	0	0	1
gardiquimod	1			2023	2023	1.0	low	0	0	1
grazoprevir	1	aromatic ether; azamacrocycle; carbamate ester; cyclopropanes; lactam; N-sulfonylcarboxamide; quinoxaline derivative	antiviral drug; hepatitis C protease inhibitor; hepatoprotective agent	2023	2023	1.0	low	0	0	1
abt-450	1			2023	2023	1.0	low	0	0	1
letermovir	1			2023	2023	1.0	low	0	0	1
sofosbuvir	1	isopropyl ester; L-alanyl ester; nucleotide conjugate; organofluorine compound; phosphoramidate ester	antiviral drug; hepatitis C protease inhibitor; prodrug	2023	2023	1.0	low	0	0	1
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine	1	benzoxazole		2023	2023	1.0	low	0	0	1
blz 945	1			2023	2023	1.0	medium	0	0	1
azd3839	1			2023	2023	1.0	medium	0	0	1
pf 3084014	1			2023	2023	1.0	low	0	0	1
unc 0638	1	quinazolines		2023	2023	1.0	low	0	0	1
gs-9620	1			2023	2023	1.0	low	0	0	1
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide	1			2023	2023	1.0	low	0	0	1
bms 708163	1	oxadiazole; ring assembly		2023	2023	1.0	low	0	0	1
jq1 compound	1	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer	2023	2023	1.0	low	0	0	1
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone	1			2023	2023	1.0	low	0	0	1
gsk525762a	1	benzodiazepine		2023	2023	1.0	low	0	0	1
ML240	1	aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound	antineoplastic agent	2023	2023	1.0	low	0	0	1
birinapant	1	dipeptide		2023	2023	1.0	low	0	0	1
ly2886721	1			2023	2023	1.0	medium	0	0	1
nms-p118	1			2023	2023	1.0	medium	0	0	1
tubastatin a	1	hydroxamic acid; pyridoindole; tertiary amino compound	EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	1

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 18, Issue:3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 21, Issue:3, 2011

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 18, Issue:3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.
Journal of medicinal chemistry, , Oct-25, Volume: 55, Issue:20, 2012

(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.
Journal of medicinal chemistry, , Jul-26, Volume: 55, Issue:14, 2012

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 18, Issue:3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	2000's	2010's	post-2020
alendronate	13	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor	2011	2018	9.1	low	1	0	13	0
nsc 664704	1	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector	2014	2014	10.0	low	0	0	1	0
midazolam	1	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative	2014	2014	10.0	low	0	0	1	0
prednisone	1	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug	2014	2014	10.0	low	0	0	1	0
uridine monophosphate	1	pyrimidine ribonucleoside 5'-monophosphate; uridine 5'-phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite	2013	2013	11.0	low	0	0	1	0
leucine	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite	2015	2015	9.0	low	0	0	1	0
phenylalanine	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite	2012	2012	12.0	low	0	0	1	0
thiophenes	2	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent	2013	2017	9.0	low	0	0	2	0
quinazolines	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines		2011	2011	13.0	low	0	0	1	0
thiazoles	2	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene		2008	2013	13.5	low	0	1	1	0
hydrazine	1	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor	2009	2009	15.0	low	0	1	0	0
thiazolidines	2	thiazolidine		2012	2015	10.5	low	0	0	2	0
glucose, (beta-d)-isomer	1	D-glucopyranose	epitope; mouse metabolite	2013	2013	11.0	low	0	0	1	0
leucine methyl ester	1	alpha-amino acid ester; L-leucine derivative; methyl ester		2015	2015	9.0	low	0	0	1	0
triazoles	1	1,2,3-triazole		2013	2013	11.0	low	0	0	1	0
zoledronic acid	2	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent	2010	2019	9.5	low	1	1	1	0
carbohydrazide	1	carbohydrazide; one-carbon compound		2009	2009	15.0	low	0	1	0	0
tanshinone	1	abietane diterpenoid	anticoronaviral agent	2016	2016	8.0	low	0	0	1	0
moxifloxacin	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug	2019	2019	5.0	low	1	0	1	0
ly 353381	1			2017	2017	7.0	low	0	0	1	0
lasofoxifene	1	aromatic ether; N-alkylpyrrolidine; naphthols; tetralins	antineoplastic agent; bone density conservation agent; cardioprotective agent; estrogen receptor agonist; estrogen receptor antagonist	2017	2017	7.0	low	0	0	1	0
n-fluorobenzenesulfonimide	1			2015	2015	9.0	low	0	0	1	0
dimethyl fumarate	1	diester; enoate ester; methyl ester	antipsoriatic; immunomodulator	2013	2013	11.0	low	0	0	1	0
digoxin	1	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope	2013	2013	11.0	low	1	0	1	0
osteoprotegerin	1	long-chain fatty acid		2009	2009	15.0	low	0	1	0	0
sphingosine	1	sphing-4-enine	human metabolite; mouse metabolite	2015	2015	9.0	low	0	0	1	0
dinoprostone	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic	2015	2015	9.0	low	0	0	1	0
cholecalciferol	1	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite	2013	2013	11.0	low	1	0	1	0
harmine	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite	2014	2014	10.0	low	0	0	1	0
maytansine	1	alpha-amino acid ester; carbamate ester; epoxide; maytansinoid; organic heterotetracyclic compound; organochlorine compound	antimicrobial agent; antimitotic; antineoplastic agent; plant metabolite; tubulin modulator	2013	2013	11.0	low	0	0	1	0
sphingosine 1-phosphate	1	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent	2015	2015	9.0	low	0	0	1	0
strontium	1	alkaline earth metal atom		2015	2015	9.0	low	0	0	1	0
fumarates	1	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite	2013	2013	11.0	low	0	0	1	0
cysteine	1	cysteinium	fundamental metabolite	2012	2012	12.0	low	0	0	1	0
relacatib	3			2008	2009	15.7	high	0	3	0	0
l-873724	4			2008	2014	13.0	high	0	2	2	0
vorapaxar	1	carbamate ester; lactone; naphthofuran; organofluorine compound; pyridines	cardiovascular drug; platelet aggregation inhibitor; protease-activated receptor-1 antagonist	2013	2013	11.0	low	0	0	1	0
balicatib	4			2008	2021	10.2	medium	0	2	1	1
saracatinib	1	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent	2011	2011	13.0	low	0	0	1	0
ono-5334	2			2012	2015	10.5	medium	0	0	2	0
acid phosphatase	1			2011	2011	13.0	low	0	0	1	0
endothelin-1	1			2012	2012	12.0	low	0	0	1	0
canagliflozin	1	C-glycosyl compound; organofluorine compound; thiophenes	hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor	2013	2013	11.0	low	0	0	1	0
suvorexant	1	1,3-benzoxazoles; aromatic amide; diazepine; organochlorine compound; triazoles	central nervous system depressant; orexin receptor antagonist	2013	2013	11.0	low	0	0	1	0
piperidines	1			2017	2017	7.0	low	0	0	1	0
sofosbuvir	1	isopropyl ester; L-alanyl ester; nucleotide conjugate; organofluorine compound; phosphoramidate ester	antiviral drug; hepatitis C protease inhibitor; prodrug	2013	2013	11.0	low	0	0	1	0
warfarin	1	benzenes; hydroxycoumarin; methyl ketone		2013	2013	11.0	low	1	0	1	0
abaloparatide	1			2014	2014	10.0	low	0	0	1	0

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	2000's	2010's	post-2020
African Sleeping Sickness	0	1	2012	2012	12.0	low	0	0	1	0
Age-Related Osteoporosis	0	42	2009	2023	9.2	medium	6	3	35	4
Alveolar Bone Atrophy	0	3	2015	2015	9.0	low	0	0	3	0
American Trypanosomiasis	0	1	2012	2012	12.0	low	0	0	1	0
Anoxemia	0	1	2012	2012	12.0	low	0	0	1	0
Apoplexy	0	1	2023	2023	1.0	low	0	0	0	1
Arthritis, Degenerative	0	1	2012	2012	12.0	low	0	0	1	0
Arthritis, Rheumatoid	0	1	2009	2009	15.0	low	0	1	0	0
Bacterial Infections, Gram-Negative	0	1	2015	2015	9.0	low	0	0	1	0
Bacteroidaceae Infections	0	1	2015	2015	9.0	low	0	0	1	0
Bejel	0	1	2015	2015	9.0	low	0	0	1	0
Benign Neoplasms	0	1	2009	2009	15.0	low	0	1	0	0
Body Weight	0	1	2020	2020	4.0	low	0	0	1	0
Bone Cancer	0	5	2008	2012	14.2	low	1	4	1	0
Bone Diseases	0	1	2015	2015	9.0	low	0	0	1	0
Bone Diseases, Metabolic	0	3	2011	2016	9.7	low	0	0	3	0
Bone Fractures	0	6	2011	2023	8.3	low	1	0	5	1
Bone Loss, Osteoclastic	0	27	2008	2022	10.5	low	5	6	19	2
Bone Loss, Perimenopausal	0	36	2008	2023	9.6	medium	14	6	26	4
Bone Neoplasms	0	5	2008	2012	14.2	low	1	4	1	0
Breast Cancer	0	5	2008	2021	9.6	low	1	2	1	2
Breast Neoplasms	1	5	2008	2021	9.6	low	1	2	1	2
Cancer of Kidney	0	1	2020	2020	4.0	low	0	0	1	0
Cancer of Prostate	0	2	2008	2012	14.0	low	0	1	1	0
Caries, Dental	0	1	2015	2015	9.0	low	0	0	1	0
Chagas Disease	0	1	2012	2012	12.0	low	0	0	1	0
Congenital Zika Syndrome	0	1	2020	2020	4.0	low	0	0	1	0
Deficiency, Vitamin D	0	1	2011	2011	13.0	low	0	0	1	0
Dental Caries	0	1	2015	2015	9.0	low	0	0	1	0
Dermatosclerosis	0	1	2021	2021	3.0	low	1	0	0	1
Diabetes Mellitus, Adult-Onset	0	1	2022	2022	2.0	low	1	0	0	1
Diabetes Mellitus, Type 2	0	1	2022	2022	2.0	low	1	0	0	1
Disease Models, Animal	0	7	2012	2020	8.4	low	0	0	7	0
Electrocardiogram QT Prolonged	0	1	2019	2019	5.0	low	1	0	1	0
Fractures, Bone	0	6	2011	2023	8.3	low	1	0	5	1
Gram-Negative Bacterial Infections	0	1	2015	2015	9.0	low	0	0	1	0
Hangman Fracture	0	2	2018	2019	5.5	low	1	0	2	0
Hip Fractures	0	3	2019	2022	3.3	low	3	0	1	2
Hypoxia	0	1	2012	2012	12.0	low	0	0	1	0
Intertrochanteric Fractures	0	3	2019	2022	3.3	low	3	0	1	2
Invasiveness, Neoplasm	0	1	2021	2021	3.0	low	0	0	0	1
Kidney Failure	0	1	2020	2020	4.0	low	0	0	1	0
Kidney Neoplasms	0	1	2020	2020	4.0	low	0	0	1	0
Leishmania Infection	0	1	2012	2012	12.0	low	0	0	1	0
Leishmaniasis	0	1	2012	2012	12.0	low	0	0	1	0
Long QT Syndrome	0	1	2019	2019	5.0	low	1	0	1	0
Low Bone Density	0	3	2011	2016	9.7	low	0	0	3	0
Margins of Excision	0	1	2019	2019	5.0	low	1	0	1	0
Mesial Drift of Teeth	0	1	2019	2019	5.0	low	0	0	1	0
Metastase	0	2	2010	2021	8.5	low	0	1	0	1
Neoplasm Metastasis	0	2	2010	2021	8.5	low	0	1	0	1
Neoplasms	0	1	2009	2009	15.0	low	0	1	0	0
Osteoarthritis	1	1	2012	2012	12.0	low	0	0	1	0
Osteolysis	0	1	2012	2012	12.0	low	0	0	1	0
Osteoporosis	1	42	2009	2023	9.2	medium	6	3	35	4
Osteoporosis, Postmenopausal	1	36	2008	2023	9.6	medium	14	6	26	4
Osteoporotic Fractures	0	12	2011	2019	8.9	low	3	0	12	0
Periapical Periodontitis	0	1	2015	2015	9.0	low	0	0	1	0
Pericementitis	0	1	2015	2015	9.0	low	0	0	1	0
Periodontitis	0	1	2015	2015	9.0	low	0	0	1	0
Periodontitis, Acute Nonsuppurative	0	1	2015	2015	9.0	low	0	0	1	0
Prostatic Neoplasms	0	2	2008	2012	14.0	low	0	1	1	0
Recrudescence	0	2	2018	2019	5.5	low	0	0	2	0
Renal Insufficiency	1	1	2020	2020	4.0	low	0	0	1	0
Rheumatoid Arthritis	0	1	2009	2009	15.0	low	0	1	0	0
Root Resorption	0	1	2015	2015	9.0	low	0	0	1	0
Scleroderma, Localized	0	1	2021	2021	3.0	low	1	0	0	1
Scleroderma, Systemic	0	1	2021	2021	3.0	low	1	0	0	1
Sclerosis, Systemic	0	1	2021	2021	3.0	low	1	0	0	1
Spinal Fractures	0	2	2018	2019	5.5	low	1	0	2	0
Stroke	0	1	2023	2023	1.0	low	0	0	0	1
Tooth Drift	0	1	2019	2019	5.0	low	0	0	1	0
Trypanosomiasis, African	0	1	2012	2012	12.0	low	0	0	1	0
Vitamin D Deficiency	0	1	2011	2011	13.0	low	0	0	1	0
Zika Virus Infection	0	1	2020	2020	4.0	low	0	0	1	0

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020

Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews, , Volume: 32, Issue:3, 2012

[Prevention of joint destruction by osteoclast-targeting therapy in search of new tools, such as OPG or cathepsin K inhibitor].
Clinical calcium, , Volume: 19, Issue:3, 2009

Pharmacological diversity among drugs that inhibit bone resorption.
Current opinion in pharmacology, , Volume: 22, 2015

Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 31, Issue:3, 2016

Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Bone, , Volume: 93, 2016

Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews, , Volume: 32, Issue:3, 2012

New approaches to treating and preventing bone metastases.
Current opinion in supportive and palliative care, , Volume: 4, Issue:3, 2010

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Clinical breast cancer, , Dec-01, Volume: 10, Issue:6, 2010

Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
IDrugs : the investigational drugs journal, , Volume: 12, Issue:12, 2009

Cathepsin K inhibitors as treatment of bone metastasis.
Current opinion in supportive and palliative care, , Volume: 2, Issue:3, 2008

Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.
Molecular biology reports, , Volume: 48, Issue:1, 2021

Inhibitory Effects of Cathepsin K Inhibitor (ODN-MK-0822) on the Paracrine Pro-Osteoclast Factors of Breast Cancer Cells.
Current molecular pharmacology, , Volume: 14, Issue:6, 2021

Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews, , Volume: 32, Issue:3, 2012

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Clinical breast cancer, , Dec-01, Volume: 10, Issue:6, 2010

Cathepsin K inhibitors as treatment of bone metastasis.
Current opinion in supportive and palliative care, , Volume: 2, Issue:3, 2008

A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.
Infection and immunity, , Volume: 83, Issue:4, 2015

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 37, Issue:11, 2022

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 37, Issue:11, 2022

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 36, Issue:7, 2021

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization.
Redox biology, , Volume: 30, 2020

Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.
Expert opinion on drug discovery, , Volume: 7, Issue:4, 2012

Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
Clinical pharmacology in drug development, , Volume: 8, Issue:7, 2019

Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.
Molecular biology reports, , Volume: 48, Issue:1, 2021

New approaches to treating and preventing bone metastases.
Current opinion in supportive and palliative care, , Volume: 4, Issue:3, 2010

Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
IDrugs : the investigational drugs journal, , Volume: 12, Issue:12, 2009

(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.
Journal of medicinal chemistry, , Jul-26, Volume: 55, Issue:14, 2012

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Archives of osteoporosis, , 05-11, Volume: 18, Issue:1, 2023

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 37, Issue:11, 2022

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 36, Issue:7, 2021

Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 32, Issue:1, 2021

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 35, Issue:7, 2020

Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
British journal of clinical pharmacology, , Volume: 85, Issue:6, 2019

A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Calcified tissue international, , Volume: 104, Issue:1, 2019

The quest for new drugs to prevent osteoporosis-related fractures.
Climacteric : the journal of the International Menopause Society, , Volume: 20, Issue:2, 2017

Merck &Co. drops osteoporosis drug odanacatib.
Nature reviews. Drug discovery, , Sep-29, Volume: 15, Issue:10, 2016

Two pioneering osteoporosis drugs finally approach approval.
Nature reviews. Drug discovery, , Jun-30, Volume: 15, Issue:7, 2016

Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Calcified tissue international, , Volume: 98, Issue:4, 2016

Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 31, Issue:3, 2016

Novel advances in the treatment of osteoporosis.
British medical bulletin, , Volume: 119, Issue:1, 2016

Short-term and long-term effects of osteoporosis therapies.
Nature reviews. Endocrinology, , Volume: 11, Issue:7, 2015

Odanacatib for the treatment of osteoporosis.
Expert opinion on pharmacotherapy, , Volume: 16, Issue:11, 2015

Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis.
Journal of bone and mineral metabolism, , Volume: 33, Issue:4, 2015

[Osteoporosis].
Revue medicale suisse, , Jan-14, Volume: 11, Issue:456-457, 2015

From Bone Cell Biology to Novel Therapies of Osteoporosis.
Drug research, , Volume: 65 Suppl 1, 2015

Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 26, Issue:2, 2015

Molecular and cellular basis of bone resorption.
Wiener medizinische Wochenschrift (1946), , Volume: 165, Issue:3-4, 2015

On the horizon: better bone-building drugs?
Mayo Clinic health letter (English ed.), , Volume: 32, Issue:12, 2014

Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses.
The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014

New therapeutics for osteoporosis.
Current opinion in pharmacology, , Volume: 16, 2014

[Drug treatment of osteoporosis].
Deutsche medizinische Wochenschrift (1946), , Volume: 139, Issue:10, 2014

Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.
Current osteoporosis reports, , Volume: 12, Issue:1, 2014

[Novel strategies for the development of anabolic agents for treatment of osteoporosis].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, , Volume: 144, Issue:6, 2014

Current and future treatments of osteoporosis in men.
Best practice & research. Clinical endocrinology & metabolism, , Volume: 28, Issue:6, 2014

Future directions for new medical entities in osteoporosis.
Best practice & research. Clinical endocrinology & metabolism, , Volume: 28, Issue:6, 2014

[Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Clinical calcium, , Volume: 24, Issue:1, 2014

Status of drug development for the prevention and treatment of osteoporosis.
Expert opinion on drug discovery, , Volume: 9, Issue:3, 2014

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 25, Issue:1, 2014

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
British journal of clinical pharmacology, , Volume: 75, Issue:5, 2013

Inhibition of cathepsin K for treatment of osteoporosis.
Current osteoporosis reports, , Volume: 10, Issue:1, 2012

Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey.
Bone, , Volume: 50, Issue:6, 2012

Potential first-in-class osteoporosis drug speeds through trials.
Nature medicine, , Volume: 18, Issue:8, 2012

[Odanacatib (MK-0822)].
Clinical calcium, , Volume: 21, Issue:1, 2011

Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

[Innovations in the treatment of osteoporosis].
Deutsche medizinische Wochenschrift (1946), , Volume: 136, Issue:48, 2011

Osteoporosis: now and the future.
Lancet (London, England), , Apr-09, Volume: 377, Issue:9773, 2011

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

[Bone remodeling: new therapeutic approaches].
Revue medicale suisse, , Jun-10, Volume: 5, Issue:207, 2009

Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 19, Issue:3, 2009

A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.
Infection and immunity, , Volume: 83, Issue:4, 2015

Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.
Journal of periodontology, , Volume: 86, Issue:8, 2015

Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews, , Volume: 32, Issue:3, 2012

Cathepsin K inhibitors as treatment of bone metastasis.
Current opinion in supportive and palliative care, , Volume: 2, Issue:3, 2008

Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.
Journal of the American Academy of Dermatology, , Volume: 84, Issue:4, 2021

Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.
Expert opinion on drug discovery, , Volume: 7, Issue:4, 2012

Osteoporosis: now and the future.
Lancet (London, England), , Apr-09, Volume: 377, Issue:9773, 2011

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Archives of osteoporosis, , 05-11, Volume: 18, Issue:1, 2023

Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 33, Issue:10, 2022

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 36, Issue:7, 2021

Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.
Journal of the American Academy of Dermatology, , Volume: 84, Issue:4, 2021

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 35, Issue:7, 2020

Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women.
Journal of clinical pharmacology, , Volume: 60, Issue:8, 2020

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 30, Issue:5, 2019

Odanacatib: the best osteoporosis treatment we never had?
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 29, Issue:4, 2018

Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 27, Issue:6, 2016

Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Biochemical pharmacology, , 10-01, Volume: 117, 2016

[Cathepsin K antagonists: preclinical and clinical data].
Wiener medizinische Wochenschrift (1946), , Volume: 165, Issue:3-4, 2015

Cathepsin K inhibitors: emerging treatment options for osteoporosis.
Wiener medizinische Wochenschrift (1946), , Volume: 165, Issue:3-4, 2015

Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
Women's health (London, England), , Volume: 11, Issue:6, 2015

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 26, Issue:2, 2015

[Biological therapy for osteoporosis].
Clinical calcium, , Volume: 24, Issue:6, 2014

Treatment of postmenopausal osteoporosis with odanacatib.
Expert opinion on pharmacotherapy, , Volume: 15, Issue:4, 2014

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 25, Issue:1, 2014

Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.
Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, , Volume: 20, Issue:3, 2013

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:12, 2013

Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:2, 2013

Potential role of odanacatib in the treatment of osteoporosis.
Clinical interventions in aging, , Volume: 7, 2012

Inhibition of cathepsin K for treatment of osteoporosis.
Current osteoporosis reports, , Volume: 10, Issue:1, 2012

[Innovations in the treatment of osteoporosis].
Deutsche medizinische Wochenschrift (1946), , Volume: 136, Issue:48, 2011

Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

Osteoporosis: now and the future.
Lancet (London, England), , Apr-09, Volume: 377, Issue:9773, 2011

[Cathepsin K inhibitor: new therapy approach against osteoporosis. Pharmacological target in the osteoclast].
MMW Fortschritte der Medizin, , May-12, Volume: 153, Issue:19, 2011

Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

New targets for intervention in the treatment of postmenopausal osteoporosis.
Nature reviews. Rheumatology, , Sep-20, Volume: 7, Issue:11, 2011

Peptidomimetic inhibitors of cathepsin K.
Current topics in medicinal chemistry, , Volume: 10, Issue:7, 2010

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 25, Issue:5, 2010

Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
Clinical pharmacology and therapeutics, , Volume: 86, Issue:2, 2009

Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
IDrugs : the investigational drugs journal, , Volume: 12, Issue:12, 2009

Molecule of the month. Odanacatib.
Drug news & perspectives, , Volume: 21, Issue:5, 2008

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 18, Issue:3, 2008

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 29, Issue:4, 2018

Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.
Journal of periodontology, , Volume: 86, Issue:8, 2015

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Archives of osteoporosis, , 05-11, Volume: 18, Issue:1, 2023

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Archives of osteoporosis, , 05-11, Volume: 18, Issue:1, 2023

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Odanacatib for the treatment of osteoporosis.
Expert opinion on pharmacotherapy, , Volume: 16, Issue:11, 2015

Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses.
The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014

Potential first-in-class osteoporosis drug speeds through trials.
Nature medicine, , Volume: 18, Issue:8, 2012

Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women.
Journal of clinical pharmacology, , Volume: 60, Issue:8, 2020

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 29, Issue:4, 2018

The quest for new drugs to prevent osteoporosis-related fractures.
Climacteric : the journal of the International Menopause Society, , Volume: 20, Issue:2, 2017

Novel advances in the treatment of osteoporosis.
British medical bulletin, , Volume: 119, Issue:1, 2016

Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Biochemical pharmacology, , 10-01, Volume: 117, 2016

Short-term and long-term effects of osteoporosis therapies.
Nature reviews. Endocrinology, , Volume: 11, Issue:7, 2015

Cathepsin K inhibitors: emerging treatment options for osteoporosis.
Wiener medizinische Wochenschrift (1946), , Volume: 165, Issue:3-4, 2015

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 26, Issue:2, 2015

[Drug treatment of osteoporosis].
Deutsche medizinische Wochenschrift (1946), , Volume: 139, Issue:10, 2014

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 25, Issue:1, 2014

Osteoporosis: now and the future.
Lancet (London, England), , Apr-09, Volume: 377, Issue:9773, 2011

[Innovations in the treatment of osteoporosis].
Deutsche medizinische Wochenschrift (1946), , Volume: 136, Issue:48, 2011

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Archives of osteoporosis, , 05-11, Volume: 18, Issue:1, 2023

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Archives of osteoporosis, , 05-11, Volume: 18, Issue:1, 2023

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Odanacatib for the treatment of osteoporosis.
Expert opinion on pharmacotherapy, , Volume: 16, Issue:11, 2015

Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses.
The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014

Potential first-in-class osteoporosis drug speeds through trials.
Nature medicine, , Volume: 18, Issue:8, 2012

Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women.
Journal of clinical pharmacology, , Volume: 60, Issue:8, 2020

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020

Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
Clinical pharmacology in drug development, , Volume: 8, Issue:7, 2019

Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews, , Volume: 32, Issue:3, 2012

[Prevention of joint destruction by osteoclast-targeting therapy in search of new tools, such as OPG or cathepsin K inhibitor].
Clinical calcium, , Volume: 19, Issue:3, 2009

Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women.
Journal of clinical pharmacology, , Volume: 60, Issue:8, 2020

Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 31, Issue:3, 2016

Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Bone, , Volume: 93, 2016

Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews, , Volume: 32, Issue:3, 2012

New approaches to treating and preventing bone metastases.
Current opinion in supportive and palliative care, , Volume: 4, Issue:3, 2010

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Clinical breast cancer, , Dec-01, Volume: 10, Issue:6, 2010

Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
IDrugs : the investigational drugs journal, , Volume: 12, Issue:12, 2009

Cathepsin K inhibitors as treatment of bone metastasis.
Current opinion in supportive and palliative care, , Volume: 2, Issue:3, 2008

Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.
Molecular biology reports, , Volume: 48, Issue:1, 2021

Inhibitory Effects of Cathepsin K Inhibitor (ODN-MK-0822) on the Paracrine Pro-Osteoclast Factors of Breast Cancer Cells.
Current molecular pharmacology, , Volume: 14, Issue:6, 2021

Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews, , Volume: 32, Issue:3, 2012

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Clinical breast cancer, , Dec-01, Volume: 10, Issue:6, 2010

Cathepsin K inhibitors as treatment of bone metastasis.
Current opinion in supportive and palliative care, , Volume: 2, Issue:3, 2008

A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.
Infection and immunity, , Volume: 83, Issue:4, 2015

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 37, Issue:11, 2022

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020

Exploration of effect of Odanacatib on inhibiting orthodontic recurrence in rats and on CatK and IGF-1 mRNA.
European review for medical and pharmacological sciences, , Volume: 23, Issue:8, 2019

Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Bone, , Volume: 93, 2016

A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.
Infection and immunity, , Volume: 83, Issue:4, 2015

Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.
Journal of periodontology, , Volume: 86, Issue:8, 2015

Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey.
Bone, , Volume: 50, Issue:6, 2012

Potential role of odanacatib in the treatment of osteoporosis.
Clinical interventions in aging, , Volume: 7, 2012

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 37, Issue:11, 2022

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 36, Issue:7, 2021

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization.
Redox biology, , Volume: 30, 2020

Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.
Expert opinion on drug discovery, , Volume: 7, Issue:4, 2012

Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
Clinical pharmacology in drug development, , Volume: 8, Issue:7, 2019

Exploration of effect of Odanacatib on inhibiting orthodontic recurrence in rats and on CatK and IGF-1 mRNA.
European review for medical and pharmacological sciences, , Volume: 23, Issue:8, 2019

Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.
Molecular biology reports, , Volume: 48, Issue:1, 2021

Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.
Molecular biology reports, , Volume: 48, Issue:1, 2021

New approaches to treating and preventing bone metastases.
Current opinion in supportive and palliative care, , Volume: 4, Issue:3, 2010

Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
IDrugs : the investigational drugs journal, , Volume: 12, Issue:12, 2009

(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.
Journal of medicinal chemistry, , Jul-26, Volume: 55, Issue:14, 2012

Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews, , Volume: 32, Issue:3, 2012

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Archives of osteoporosis, , 05-11, Volume: 18, Issue:1, 2023

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 37, Issue:11, 2022

Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 32, Issue:1, 2021

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 36, Issue:7, 2021

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 35, Issue:7, 2020

A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Calcified tissue international, , Volume: 104, Issue:1, 2019

Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
British journal of clinical pharmacology, , Volume: 85, Issue:6, 2019

The quest for new drugs to prevent osteoporosis-related fractures.
Climacteric : the journal of the International Menopause Society, , Volume: 20, Issue:2, 2017

Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Calcified tissue international, , Volume: 98, Issue:4, 2016

Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 31, Issue:3, 2016

Two pioneering osteoporosis drugs finally approach approval.
Nature reviews. Drug discovery, , Jun-30, Volume: 15, Issue:7, 2016

Novel advances in the treatment of osteoporosis.
British medical bulletin, , Volume: 119, Issue:1, 2016

Merck &Co. drops osteoporosis drug odanacatib.
Nature reviews. Drug discovery, , Sep-29, Volume: 15, Issue:10, 2016

Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis.
Journal of bone and mineral metabolism, , Volume: 33, Issue:4, 2015

From Bone Cell Biology to Novel Therapies of Osteoporosis.
Drug research, , Volume: 65 Suppl 1, 2015

[Osteoporosis].
Revue medicale suisse, , Jan-14, Volume: 11, Issue:456-457, 2015

Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 26, Issue:2, 2015

Odanacatib for the treatment of osteoporosis.
Expert opinion on pharmacotherapy, , Volume: 16, Issue:11, 2015

Short-term and long-term effects of osteoporosis therapies.
Nature reviews. Endocrinology, , Volume: 11, Issue:7, 2015

Molecular and cellular basis of bone resorption.
Wiener medizinische Wochenschrift (1946), , Volume: 165, Issue:3-4, 2015

[Novel strategies for the development of anabolic agents for treatment of osteoporosis].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, , Volume: 144, Issue:6, 2014

Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses.
The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014

New therapeutics for osteoporosis.
Current opinion in pharmacology, , Volume: 16, 2014

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 25, Issue:1, 2014

[Drug treatment of osteoporosis].
Deutsche medizinische Wochenschrift (1946), , Volume: 139, Issue:10, 2014

Current and future treatments of osteoporosis in men.
Best practice & research. Clinical endocrinology & metabolism, , Volume: 28, Issue:6, 2014

Status of drug development for the prevention and treatment of osteoporosis.
Expert opinion on drug discovery, , Volume: 9, Issue:3, 2014

Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.
Current osteoporosis reports, , Volume: 12, Issue:1, 2014

Future directions for new medical entities in osteoporosis.
Best practice & research. Clinical endocrinology & metabolism, , Volume: 28, Issue:6, 2014

[Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Clinical calcium, , Volume: 24, Issue:1, 2014

On the horizon: better bone-building drugs?
Mayo Clinic health letter (English ed.), , Volume: 32, Issue:12, 2014

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
British journal of clinical pharmacology, , Volume: 75, Issue:5, 2013

Potential first-in-class osteoporosis drug speeds through trials.
Nature medicine, , Volume: 18, Issue:8, 2012

Inhibition of cathepsin K for treatment of osteoporosis.
Current osteoporosis reports, , Volume: 10, Issue:1, 2012

Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey.
Bone, , Volume: 50, Issue:6, 2012

[Odanacatib (MK-0822)].
Clinical calcium, , Volume: 21, Issue:1, 2011

[Innovations in the treatment of osteoporosis].
Deutsche medizinische Wochenschrift (1946), , Volume: 136, Issue:48, 2011

Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

Osteoporosis: now and the future.
Lancet (London, England), , Apr-09, Volume: 377, Issue:9773, 2011

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 19, Issue:3, 2009

[Bone remodeling: new therapeutic approaches].
Revue medicale suisse, , Jun-10, Volume: 5, Issue:207, 2009

A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.
Infection and immunity, , Volume: 83, Issue:4, 2015

Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.
Journal of periodontology, , Volume: 86, Issue:8, 2015

Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews, , Volume: 32, Issue:3, 2012

Cathepsin K inhibitors as treatment of bone metastasis.
Current opinion in supportive and palliative care, , Volume: 2, Issue:3, 2008

Exploration of effect of Odanacatib on inhibiting orthodontic recurrence in rats and on CatK and IGF-1 mRNA.
European review for medical and pharmacological sciences, , Volume: 23, Issue:8, 2019

Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 29, Issue:4, 2018

Effect of odanacatib on root resorption and alveolar bone metabolism during orthodontic tooth movement.
Genetics and molecular research : GMR, , Dec-22, Volume: 14, Issue:4, 2015

Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.
Journal of the American Academy of Dermatology, , Volume: 84, Issue:4, 2021

Exploration of effect of Odanacatib on inhibiting orthodontic recurrence in rats and on CatK and IGF-1 mRNA.
European review for medical and pharmacological sciences, , Volume: 23, Issue:8, 2019

Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.
Journal of periodontology, , Volume: 86, Issue:8, 2015

Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.
Expert opinion on drug discovery, , Volume: 7, Issue:4, 2012

Osteoporosis: now and the future.
Lancet (London, England), , Apr-09, Volume: 377, Issue:9773, 2011

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Archives of osteoporosis, , 05-11, Volume: 18, Issue:1, 2023

Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 33, Issue:10, 2022

Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.
Journal of the American Academy of Dermatology, , Volume: 84, Issue:4, 2021

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 36, Issue:7, 2021

Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women.
Journal of clinical pharmacology, , Volume: 60, Issue:8, 2020

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 35, Issue:7, 2020

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Odanacatib: the best osteoporosis treatment we never had?
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 30, Issue:5, 2019

Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 29, Issue:4, 2018

Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 27, Issue:6, 2016

Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Biochemical pharmacology, , 10-01, Volume: 117, 2016

Cathepsin K inhibitors: emerging treatment options for osteoporosis.
Wiener medizinische Wochenschrift (1946), , Volume: 165, Issue:3-4, 2015

[Cathepsin K antagonists: preclinical and clinical data].
Wiener medizinische Wochenschrift (1946), , Volume: 165, Issue:3-4, 2015

Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
Women's health (London, England), , Volume: 11, Issue:6, 2015

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 26, Issue:2, 2015

[Biological therapy for osteoporosis].
Clinical calcium, , Volume: 24, Issue:6, 2014

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 25, Issue:1, 2014

Treatment of postmenopausal osteoporosis with odanacatib.
Expert opinion on pharmacotherapy, , Volume: 15, Issue:4, 2014

Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:2, 2013

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:12, 2013

Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.
Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, , Volume: 20, Issue:3, 2013

Potential role of odanacatib in the treatment of osteoporosis.
Clinical interventions in aging, , Volume: 7, 2012

Inhibition of cathepsin K for treatment of osteoporosis.
Current osteoporosis reports, , Volume: 10, Issue:1, 2012

New targets for intervention in the treatment of postmenopausal osteoporosis.
Nature reviews. Rheumatology, , Sep-20, Volume: 7, Issue:11, 2011

[Cathepsin K inhibitor: new therapy approach against osteoporosis. Pharmacological target in the osteoclast].
MMW Fortschritte der Medizin, , May-12, Volume: 153, Issue:19, 2011

Osteoporosis: now and the future.
Lancet (London, England), , Apr-09, Volume: 377, Issue:9773, 2011

Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

[Innovations in the treatment of osteoporosis].
Deutsche medizinische Wochenschrift (1946), , Volume: 136, Issue:48, 2011

Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2, 2011

Peptidomimetic inhibitors of cathepsin K.
Current topics in medicinal chemistry, , Volume: 10, Issue:7, 2010

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 25, Issue:5, 2010

Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
Clinical pharmacology and therapeutics, , Volume: 86, Issue:2, 2009

Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
IDrugs : the investigational drugs journal, , Volume: 12, Issue:12, 2009

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 18, Issue:3, 2008

Molecule of the month. Odanacatib.
Drug news & perspectives, , Volume: 21, Issue:5, 2008

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
The lancet. Diabetes & endocrinology, , Volume: 7, Issue:12, 2019

Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 29, Issue:4, 2018

Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.
Journal of periodontology, , Volume: 86, Issue:8, 2015

Effect of odanacatib on root resorption and alveolar bone metabolism during orthodontic tooth movement.
Genetics and molecular research : GMR, , Dec-22, Volume: 14, Issue:4, 2015

A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.
Infection and immunity, , Volume: 83, Issue:4, 2015

Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.
Journal of periodontology, , Volume: 86, Issue:8, 2015

odanacatib

Description

Cross-References

Synonyms (58)

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Bioassays (121)

Research

Studies (147)

Study Types

Safety/Toxicity (6)

Long-term Use (3)

Pharmacokinetics (9)

Bioavailability (9)

Dosage (8)

Interactions (1)

Article	Year
Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis. Archives of osteoporosis, , 05-11, Volume: 18, Issue:1	2023
Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 32, Issue:1	2021
Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects. Clinical pharmacology in drug development, , Volume: 8, Issue:7	2019
Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis. Journal of bone and mineral metabolism, , Volume: 33, Issue:4	2015
Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:12	2013
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. British journal of clinical pharmacology, , Volume: 75, Issue:5	2013

Article	Year
Novel advances in the treatment of osteoporosis. British medical bulletin, , Volume: 119, Issue:1	2016
Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy. Biochemical pharmacology, , 10-01, Volume: 117	2016
Cathepsin K inhibitors as treatment of bone metastasis. Current opinion in supportive and palliative care, , Volume: 2, Issue:3	2008

Article	Year
Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women. Journal of clinical pharmacology, , Volume: 60, Issue:8	2020
The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women. Drug metabolism and disposition: the biological fate of chemicals, , Volume: 44, Issue:9	2016
Development and validation of an RP-HPLC method for the quantitation of odanacatib in rat and human plasma and its application to a pharmacokinetic study. Biomedical chromatography : BMC, , Volume: 29, Issue:11	2015
Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib. Journal of clinical pharmacology, , Volume: 54, Issue:11	2014
Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women. The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:2	2014
Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, , Volume: 20, Issue:3	2013
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. British journal of clinical pharmacology, , Volume: 75, Issue:5	2013
Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors. Journal of medicinal chemistry, , Oct-25, Volume: 55, Issue:20	2012
Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:6	2011

Article	Year
Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects. Clinical pharmacology in drug development, , Volume: 8, Issue:7	2019
Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis. British journal of clinical pharmacology, , Volume: 85, Issue:6	2019
Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis. Calcified tissue international, , Volume: 98, Issue:4	2016
Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits. BMC musculoskeletal disorders, , Dec-09, Volume: 14	2013
High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate. Bone, , Volume: 56, Issue:2	2013
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. British journal of clinical pharmacology, , Volume: 75, Issue:5	2013
Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 26, Issue:2	2011
Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clinical pharmacology and therapeutics, , Volume: 86, Issue:2	2009

odanacatib

Description

Cross-References

Synonyms (58)

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Bioassays (121)

Research

Studies (147)

Study Types

Related Drugs (595)

Drugs Involved in Assays Together (555)

Drugs Researched Together (48)

Related Conditions (75)

Safety/Toxicity (6)

Long-term Use (3)

Pharmacokinetics (9)

Bioavailability (9)

Dosage (8)

Interactions (1)